(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.35%) $82.72
(6.19%) $2.04
(-0.03%) $2 346.60
(-0.27%) $27.46
(3.86%) $957.65
(-0.22%) $0.933
(-0.36%) $10.98
(-0.54%) $0.796
(1.67%) $93.41
@ $1.954
Išleistas: 14 vas. 2024 @ 16:32
Grąža: -26.56%
Ankstesnis signalas: vas. 7 - 23:00
Ankstesnis signalas:
Grąža: 1.24 %
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
Šios dienos apimtis | 340 932 |
Vidutinė apimtis | 430 161 |
Rinkos kapitalizacija | 50.21M |
EPS | $0 ( 2024-04-04 ) |
Kita pelno data | ( $-0.370 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.450 |
ATR14 | $0.00500 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
INSIDER POWER |
---|
82.65 |
Last 98 transactions |
Buy: 5 337 828 | Sell: 1 367 663 |
Tūris Koreliacija
Checkpoint Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
RMRM | 0.94 |
TLGT | 0.938 |
SVAC | 0.937 |
AGFY | 0.934 |
PAIC | 0.934 |
CCCC | 0.931 |
ALT | 0.931 |
JOAN | 0.93 |
VERU | 0.928 |
EYEG | 0.922 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
NETE | -0.95 |
MMAC | -0.934 |
STAY | -0.927 |
BNIXU | -0.92 |
CCRC | -0.92 |
NVCN | -0.912 |
DSPG | -0.911 |
XM | -0.909 |
FEXD | -0.901 |
AVEO | -0.896 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Checkpoint Therapeutics Koreliacija - Valiuta/Žaliavos
Checkpoint Therapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $103 000 |
Bruto pelnas: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2023 |
Pajamos: | $103 000 |
Bruto pelnas: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2022 |
Pajamos: | $192 000 |
Bruto pelnas: | $-49.63M (-25 850.52 %) |
EPS: | $-7.57 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-10.15 |
Financial Reports:
No articles found.
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.